Hubbry Logo
Process chemistryProcess chemistryMain
Open search
Process chemistry
Community hub
Process chemistry
logo
7 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Process chemistry
Process chemistry
Process chemistry
View on Wikipedia
from Wikipedia

Process chemistry is the arm of pharmaceutical chemistry concerned with the development and optimization of a synthetic scheme and pilot plant procedure to manufacture compounds for the drug development phase. Process chemistry is distinguished from medicinal chemistry, which is the arm of pharmaceutical chemistry tasked with designing and synthesizing molecules on small scale in the early drug discovery phase.

Medicinal chemists are largely concerned with synthesizing a large number of compounds as quickly as possible from easily tunable chemical building blocks (usually for SAR studies). In general, the repertoire of reactions utilized in discovery chemistry is somewhat narrow (for example, the Buchwald-Hartwig amination, Suzuki coupling and reductive amination are commonplace reactions).[1] In contrast, process chemists are tasked with identifying a chemical process that is safe, cost and labor efficient, “green,” and reproducible, among other considerations. Oftentimes, in searching for the shortest, most efficient synthetic route, process chemists must devise creative synthetic solutions that eliminate costly functional group manipulations and oxidation/reduction steps.

This article focuses exclusively on the chemical and manufacturing processes associated with the production of small molecule drugs. Biological medical products (more commonly called “biologics”) represent a growing proportion of approved therapies, but the manufacturing processes of these products are beyond the scope of this article. Additionally, the many complex factors associated with chemical plant engineering (for example, heat transfer and reactor design) and drug formulation will be treated cursorily.

Considerations in process chemistry

[edit]

Cost efficiency is of paramount importance in process chemistry and, consequently, is a focus in the consideration of pilot plant synthetic routes. The drug substance that is manufactured, prior to the formulation, is commonly referred to as the active pharmaceutical ingredient (API) and will be referred to as such herein. API production cost can be broken into two components: the “material cost” and the “conversion cost.”[2] The ecological and environmental impact of a synthetic process should also be evaluated by an appropriate metric (e.g. the EcoScale).

An ideal process chemical route will score well in each of these metrics, but inevitably tradeoffs are to be expected. Most large pharmaceutical process chemistry and manufacturing divisions have devised weighted quantitative schemes to measure the overall attractiveness of a given synthetic route over another. As cost is a major driver, material cost and volume-time output are typically weighted heavily.

Material cost

[edit]

The material cost of a chemical process is the sum of the costs of all raw materials, intermediates, reagents, solvents, and catalysts procured from external vendors. Material costs may influence the selection of one synthetic route over another or the decision to outsource production of an intermediate.

Conversion cost

[edit]

The conversion cost of a chemical process is a factor of that procedure's overall efficiency, both in materials and time, and its reproducibility. The efficiency of a chemical process can be quantified by its atom economy, yield, volume-time output, and environmental factor (E-factor), and its reproducibility can be evaluated by the Quality Service Level (QSL) and Process Excellence Index (PEI) metrics.

An illustrative example of atom economy using the Claisen rearrangement and Wittig reaction.

Atom economy

[edit]

The atom economy of a reaction is defined as the number of atoms from the starting materials that are incorporated into the final product. Atom economy can be viewed as an indicator of the “efficiency” of a given synthetic route.[3]

For example, the Claisen rearrangement and the Diels-Alder cycloaddition are examples of reactions that are 100 percent atom economical. On the other hand, a prototypical Wittig reaction has an especially poor atom economy (merely 20 percent in the example shown).

Process synthetic routes should be designed such that atom economy is maximized for the entire synthetic scheme. Consequently, “costly” reagents such as protecting groups and high molecular weight leaving groups should be avoided where possible. An atom economy value in the range of 70 to 90 percent for an API synthesis is ideal, but it may be impractical or impossible to access certain complex targets within this range. Nevertheless, atom economy is a good metric to compare two routes to the same molecule.

Yield

[edit]

Yield is defined as the amount of product obtained in a chemical reaction. The yield of practical significance in process chemistry is the isolated yield—the yield of the isolated product after all purification steps. In a final API synthesis, isolated yields of 80 percent or above for each synthetic step are expected. The definition of an acceptable yield depends entirely on the importance of the product and the ways in which available technologies come together to allow their efficient application; yields approaching 100% are termed quantitative, and yields above 90% are broadly understood as excellent.[4]

There are several strategies that are employed in the design of a process route to ensure the adequate overall yield of the pharmaceutical product. The first is the concept of convergent synthesis. Assuming a very good to excellent yield in each synthetic step, the overall yield of a multistep reaction can be maximized by combining several key intermediates at a late stage that are prepared independently from each other.

Another strategy to maximize isolated yield (as well as time efficiency) is the concept of telescoping synthesis (also called one-pot synthesis). This approach describes the process of eliminating workup and purification steps from a reaction sequence, typically by simply adding reagents sequentially to a reactor. In this way, unnecessary losses from these steps can be avoided.

Finally, to minimize overall cost, synthetic steps involving expensive reagents, solvents, or catalysts should be designed into the process route as late stage as possible, to minimize the amount of reagent used.

In a pilot plant or manufacturing plant setting, yield can have a profound effect on the material cost of an API synthesis, so the careful planning of a robust route and the fine-tuning of reaction conditions are crucially important. After a synthetic route has been selected, process chemists will subject each step to exhaustive optimization in order to maximize the overall yield. Low yields are typically indicative of unwanted side product formation, which can raise red flags in the regulatory process as well as pose challenges for reactor cleaning operations.

Volume-time output

[edit]

The volume-time output (VTO) of a chemical process represents the cost of occupancy of a chemical reactor for a particular process or API synthesis. For example, a high VTO indicates that a particular synthetic step is costly in terms of “reactor hours” used for a given output. Mathematically, the VTO for a particular process is calculated by the total volume of all reactors (m3) that are occupied times the hours per batch divided by the output for that batch of API or intermediate (measured in kg).

The process chemistry group at Boehringer Ingelheim, for example, targets a VTO of less than 1 for any given synthetic step or chemical process.

Additionally, the raw conversion cost of an API synthesis (in dollars per batch) can be calculated from the VTO, given the operating cost and usable capacity of a particular reactor. Oftentimes, for large-volume APIs, it is economical to build a dedicated production plant rather than to use space in general pilot plants or manufacturing plants.

Environmental factor (e-factor) and process mass intensity (PMI)

[edit]

Both of these measures, which capture the environmental impact of a synthetic reaction, intend to capture the significant and rising cost of waste disposal in the manufacturing process. The E-factor for an entire API process is computed by the ratio of the total mass of waste generated in the synthetic scheme to the mass of product isolated.

A similar measure, the process mass intensity (PMI) calculates the ratio of the total mass of materials to the mass of the isolated product.

For both metrics, all materials used in all synthetic steps, including reaction and workup solvents, reagents, and catalysts, are counted, even if solvents or catalysts are recycled in practice. Inconsistencies in E-factor or PMI computations may arise when choosing to consider the waste associated with the synthesis of outsourced intermediates or common reagents. Additionally, the environmental impact of the generated waste is ignored in this calculation; therefore, the environmental quotient (EQ) metric was devised, which multiplies the E-factor by an “unfriendliness quotient” associated with various waste streams. A reasonable target for the E-factor or PMI of a single synthetic step is any value between 10 and 40.

Quality service level (QSL)

[edit]

The final two "conversion cost" considerations involve the reproducibility of a given reaction or API synthesis route. The quality service level (QSL) is a measure of the reproducibility of the quality of the isolated intermediate or final API. While the details of computing this value are slightly nuanced and unimportant for the purposes of this article, in essence, the calculation involves the ratio of satisfactory quality batches to the total number of batches. A reasonable QSL target is 98 to 100 percent.

Process excellence index (PEI)

[edit]

Like the QSL, the process excellence index (PEI) is a measure of process reproducibility. Here, however, the robustness of the procedure is evaluated in terms of yield and cycle time of various operations. The PEI yield is defined as follows:

In practice, if a process is high-yielding and has a narrow distribution of yield outcomes, then the PEI should be very high. Processes that are not easily reproducible may have a higher aspiration level yield and a lower average yield, lowering the PEI yield.

Similarly, a PEI cycle time may be defined as follows:

For this expression, the terms are inverted to reflect the desirability of shorter cycle times (as opposed to higher yields). The reproducibility of cycle times for critical processes such as reaction, centrifugation, or drying may be critical if these operations are rate-limiting in the manufacturing plant setting. For example, if an isolation step is particularly difficult or slow, it could become the bottleneck for API synthesis, in which case the reproducibility and optimization of that operation become critical.

For an API manufacturing process, all PEI metrics (yield and cycle times) should be targeted at 98 to 100 percent.

EcoScale

[edit]

In 2006, Van Aken, et al.[5] developed a quantitative framework to evaluate the safety and ecological impact of a chemical process, as well as minor weighting of practical and economical considerations. Others have modified this EcoScale by adding, subtracting and adjusting the weighting of various metrics. Among other factors, the EcoScale takes into account the toxicity, flammability, and explosive stability of reagents used, any nonstandard or potentially hazardous reaction conditions (for example, elevated pressure or inert atmosphere), and reaction temperature. Some EcoScale criteria are redundant with previously considered criteria (e.g. E-factor).

Synthetic case studies

[edit]

Boehringer Ingelheim HCV protease inhibitor (BI 201302)

[edit]

Macrocyclization is a recurrent challenge for process chemists, and large pharmaceutical companies have necessarily developed creative strategies to overcome these inherent limitations. An interesting case study in this area involves the development of novel NS3 protease inhibitors to treat Hepatitis C patients by scientists at Boehringer Ingelheim.[6] The process chemistry team at BI was tasked with developing a cheaper and more efficient route to the active NS3 inhibitor BI 201302, a close analog of BILN 2061. Two significant shortcomings were immediately identified with the initial scale-up route to BILN 2061, depicted in the scheme below.[7] The macrocyclization step posed four challenges inherent to the cross-metathesis reaction.

  1. High dilution is typically necessary to prevent unwanted dimerization and oligomerization of the diene starting material. In a pilot plant setting, however, a high dilution factor translates into lower throughput, higher solvent costs and higher waste costs.
  2. High catalyst loading was found to be necessary to drive the RCM reaction to completion. Because of the high licensing costs of the ruthenium catalyst that was used (1st generation Hoveyda catalyst), a high catalyst loading was financially prohibitive. Recycling of the catalyst was explored but proved impractical.
  3. Long reaction times were necessary for reaction completion, due to the slow kinetics of the reaction using the selected catalyst. It was hypothesized that this limitation could be overcome using a more active catalyst. However, while the second-generation Hoveyda and Grubbs catalysts were kinetically more active than the first-generation catalyst, reactions using these catalysts formed large amounts of dimeric and oligomeric products.
  4. An epimerization risk under the cross-metathesis reaction conditions. The process chemistry group at Boehringer Ingelheim performed extensive mechanistic studies showing that epimerization most likely occurs through a ruthenacyclopentene intermediate.[8] Furthermore, the Hoveyda catalyst employed in this scheme minimizes epimerization risk compared with the analogous Grubbs catalyst.

Additionally, the final double SN2 sequence to install the quinoline heterocycle was identified as a secondary inefficiency in the synthetic route.

Analysis of the cross-metathesis reaction revealed that the conformation of the acyclic precursor had a profound impact on the formation of dimers and oligomers in the reaction mixture. By installing a Boc protecting group at the C-4 amide nitrogen, the Boehringer Ingelheim chemists were able to shift the site of initiation from the vinylcyclopropane moiety to the nonenoic acid moiety, improving the rate of the intramolecular reaction and decreasing the risk of epimerization. Additionally, the catalyst employed was switched from the expensive 1st generation Hoveyda catalyst to the more reactive, less expensive Grela catalyst.[9] These modifications allowed the process chemists to run the reaction at a standard reaction dilution of 0.1-0.2 M, given that the rates of competing dimerization and oligomerization reactions was so dramatically reduced.

Additionally, the process chemistry team envisioned a SNAr strategy to install the quinoline heterocycle, instead of the SN2 strategy that they had employed for the synthesis of BILN 2061. This modification prevented the need for inefficient double inversion by proceeding through retention of stereochemistry at the C-4 position of the hydroxyproline moiety.[10]

It is interesting to examine this case study from a VTO perspective. For the unoptimized cross-metathesis reaction using the Grela catalyst at 0.01 M diene, the reaction yield was determined to be 82 percent after a reaction and workup time of 48 hours. A 6-cubic meter reactor filled to 80% capacity afforded 35 kg of the desired product. For the unoptimized reaction:

This VTO value was considered prohibitively high and a steep investment in a dedicated plant would have been necessary even before launching Phase III trials with this API, given its large projected annual demand. But after reaction development and optimization, the process team was able to improve the reaction yield to 93 percent after just 1 hour (plus 12 hours for workup and reactor cleaning time) at a diene concentration of 0.2 M. With these modifications, a 6-cubic meter reactor filled to 80% capacity afforded 799 kg of the desired product. For this optimized reaction:

Thus, after optimization, this synthetic step became less costly in terms of equipment and time and more practical to perform in a standard manufacturing facility, eliminating the need for costly investment in a new dedicated plant.

Additional topics

[edit]

Transition-metal catalysis and organocatalysis

[edit]

Biocatalysis and enzymatic engineering

[edit]

Recently, large pharmaceutical process chemists have relied heavily on the development of enzymatic reactions to produce important chiral building blocks for API synthesis. Many varied classes of naturally occurring enzymes have been co-opted and engineered for process pharmaceutical chemistry applications. The widest range of applications come from ketoreductases and transaminases, but there are isolated examples from hydrolases, aldolases, oxidative enzymes, esterases and dehalogenases, among others.[11]

One of the most prominent uses of biocatalysis in process chemistry today is in the synthesis of Januvia®, a DPP-4 inhibitor developed by Merck for the management of type II diabetes. The traditional process synthetic route involved a late-stage enamine formation followed by rhodium-catalyzed asymmetric hydrogenation to afford the API sitagliptin. This process suffered from a number of limitations, including the need to run the reaction under a high-pressure hydrogen environment, the high cost of a transition-metal catalyst, the difficult process of carbon treatment to remove trace amounts of catalyst and insufficient stereoselectivity, requiring a subsequent recrystallization step before final salt formation.[12][13]

Comparison of the chemosynthetic and biosynthetic routes toward sitagliptin.
Comparison of the chemosynthetic and biosynthetic routes toward sitagliptin.

Merck's process chemistry department contracted Codexis, a medium-sized biocatalysis firm, to develop a large-scale biocatalytic reductive amination for the final step of its sitagliptin synthesis. Codexis engineered a transaminase enzyme from the bacteria Arthrobacter through 11 rounds of directed evolution. The engineered transaminase contained 27 individual point mutations and displayed activity four orders of magnitude greater than the parent enzyme. Additionally, the enzyme was engineered to handle high substrate concentrations (100 g/L) and to tolerate the organic solvents, reagents and byproducts of the transamination reaction. This biocatalytic route successfully avoided the limitations of the chemocatalyzed hydrogenation route: the requirements to run the reaction under high pressure, to remove excess catalyst by carbon treatment and to recrystallize the product due to insufficient enantioselectivity were obviated by the use of a biocatalyst. Merck and Codexis were awarded the Presidential Green Chemistry Challenge Award in 2010 for the development of this biocatalytic route toward Januvia®.[14]

Continuous/flow manufacturing

[edit]

In recent years, much progress has been made in the development and optimization of flow reactors for small-scale chemical synthesis (the Jamison Group Archived 2022-04-24 at the Wayback Machine at MIT and Ley Group at Cambridge University, among others, have pioneered efforts in this field). The pharmaceutical industry, however, has been slow to adopt this technology for large-scale synthetic operations. For certain reactions, however, continuous processing may possess distinct advantages over batch processing in terms of safety, quality, and throughput.

A case study of particular interest involves the development of a fully continuous process by the process chemistry group at Eli Lilly and Company for an asymmetric hydrogenation to access a key intermediate in the synthesis of LY500307,[15] a potent ERβ agonist that is entering clinical trials for the treatment of patients with schizophrenia, in addition to a regimen of standard antipsychotic medications. In this key synthetic step, a chiral rhodium-catalyst is used for the enantioselective reduction of a tetrasubstituted olefin. After extensive optimization, it was found that in order to reduce the catalyst loading to a commercially practical level, the reaction required hydrogen pressure up to 70 atm. The pressure limit of a standard chemical reactor is about 10 atm, although high-pressure batch reactors may be acquired at significant capital cost for reactions up to 100 atm. Especially for an API in the early stages of chemical development, such an investment clearly bears a large risk.

An additional concern was that the hydrogenation product has an unfavorable eutectic point, so it was impossible to isolate the crude intermediate in more than 94 percent ee by batch process. Because of this limitation, the process chemistry route toward LY500307 necessarily involved a kinetically controlled crystallization step after the hydrogenation to upgrade the enantiopurity of this penultimate intermediate to >99 percent ee.

Comparison of the batch and continuous flow processes toward LY500307.
Comparison of the batch and continuous flow processes toward LY500307.

The process chemistry team at Eli Lilly successfully developed a fully continuous process to this penultimate intermediate, including reaction, workup and kinetically controlled crystallization modules (the engineering considerations implicit in these efforts are beyond the scope of this article). An advantage of flow reactors is that high-pressure tubing can be utilized for hydrogenation and other hyperbaric reactions. Because the headspace of a batch reactor is eliminated, however, many of the safety concerns associated with running high-pressure reactions are obviated by the use of a continuous process reactor. Additionally, a two-stage mixed suspension-mixed product removal (MSMPR) module was designed for the scalable, continuous, kinetically controlled crystallization of the product, so it was possible to isolate in >99 percent ee, eliminating the need for an additional batch crystallization step.

This continuous process afforded 144 kg of the key intermediate in 86 percent yield, comparable with a 90 percent isolated yield using the batch process. This 73-liter pilot-scale flow reactor (occupying less than 0.5 m3 space) achieved the same weekly throughput as theoretical batch processing in a 400-liter reactor. Therefore, the continuous flow process demonstrates advantages in safety, efficiency (eliminates the need for batch crystallization), and throughput, compared with a theoretical batch process.

Academic research institutes in process chemistry

[edit]

Institute of Process Research & Development, University of Leeds

References

[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Process chemistry

View on Grokipedia
from Grokipedia
Process chemistry is the branch of focused on the development, optimization, and implementation of practical synthetic processes for the large-scale production of chemicals, particularly pharmaceuticals, agrochemicals, and fine chemicals. It bridges the gap between small-scale laboratory research and industrial by redesigning synthetic routes to ensure they are robust, safe, cost-effective, and environmentally sustainable, while achieving high yields, purity, and minimal impurities. In the , process chemists take compounds identified during discovery research and transform them into viable commercial products through scalable synthesis. This involves testing reaction plans, monitoring processes with analytical methods, troubleshooting inefficiencies, and using simulation tools to predict outcomes, all while adhering to strict regulatory requirements for and . Key considerations include selecting inexpensive and benign , maximizing to reduce waste, and ensuring high selectivity to avoid hazardous byproducts. The field has evolved significantly over the past three decades, with growing emphasis on principles to minimize environmental impact and enhance sustainability in chemical manufacturing. Unlike , which prioritizes rapid compound discovery, process chemistry emphasizes practicality and from the outset, often requiring iterative improvements to handle the complexities of pilot and full-scale operations. Professionals in this area typically hold degrees in chemistry or and gain expertise through , contributing to innovations that accelerate product development and market readiness.

Overview

Definition and Scope

Process chemistry is the scientific discipline focused on the development, optimization, and of chemical processes to produce organic compounds—whether novel or established—on a large scale, transitioning from laboratory-scale synthesis to industrial production. This field bridges the gap between discovery research and commercial by designing robust synthetic routes that can be reliably scaled while addressing practical challenges in production. The primary objectives of process chemistry include ensuring operational safety to prevent hazards like thermal runaways, maximizing through high yields and minimal , achieving cost-effectiveness via reduced material and energy inputs, and maintaining environmental compliance by minimizing emissions and resource consumption. These goals are pursued through iterative that incorporates metrics such as yield for productivity and E-factor for assessment, though detailed evaluation occurs in specialized analyses. The scope of process chemistry extends across multiple industrial sectors, including pharmaceuticals where it supports drug substance synthesis under stringent regulatory oversight, chemicals for specialty products like dyes and flavors, bulk chemicals for high-volume commodities such as polymers, and agrochemicals for pesticides and fertilizers. In contrast to laboratory chemistry, which prioritizes exploratory synthesis and small-batch experimentation, process chemistry emphasizes process robustness to handle variations in raw materials and conditions, stringent impurity control to meet purity specifications, and adherence to regulatory standards like (GMP) for consistent quality in pharmaceuticals. Within the chemical , process chemists contribute from initial route scouting to identify viable synthetic pathways, through optimization for scale-up, to full commercialization ensuring reliable production and market viability.

Historical Development

Process chemistry originated during the 19th-century , as chemists began developing scalable synthetic methods for organic compounds to meet growing industrial demands. A pivotal moment came in 1856 when , an 18-year-old student, accidentally synthesized , the first commercial synthetic dye, from derived from . This discovery not only launched the synthetic dye industry but also demonstrated the feasibility of large-scale , shifting chemistry from natural extracts to engineered processes. Concurrently, the development of explosives processes advanced industrial capabilities; for instance, Ascanio Sobrero's 1847 synthesis of and Alfred Nobel's 1867 invention of introduced techniques that required precise control over reaction conditions for safe, high-yield production. In the early , process chemistry matured with breakthroughs in that enabled massive-scale production. The Haber-Bosch process, developed by and around 1910, revolutionized synthesis by combining and under high pressure and temperature with an iron catalyst, providing a foundation for fertilizer production and large-scale catalytic engineering. This method's success underscored the importance of integrating fundamental with engineering for industrial viability. Wilhelm Ostwald's foundational work on , recognized with the 1909 , further propelled the field by defining as the acceleration of reactions by foreign substances without consumption, influencing processes like the for . Following , process chemistry experienced explosive growth in the pharmaceutical sector, driven by the urgent need for antibiotics. In the 1940s, researchers at companies like scaled up penicillin production using deep-tank , transforming Howard Florey's 1940 laboratory extraction into a wartime industrial process that yielded millions of doses by 1945. This era marked a shift toward complex, stereoselective syntheses, exemplified by K. Barry Sharpless's development of asymmetric epoxidation in the , which enabled efficient scaling of chiral drug intermediates and earned him the 2001 . By the 1990s, environmental concerns prompted a pivot to , formalized by and John Warner's 12 principles in response to the U.S. Pollution Prevention Act of 1990, emphasizing waste reduction and sustainable processes. Regulatory frameworks further shaped process design, particularly through the U.S. Clean Air Act of , which mandated emission controls and spurred innovations in pollution abatement within chemical manufacturing, such as catalytic converters and cleaner reaction pathways. These laws compelled the industry to integrate safety and environmental considerations into core process optimization, influencing global standards for chemical production.

Core Principles

Scalability and Safety

Scalability in process chemistry involves translating laboratory-scale reactions to industrial production, where challenges arise primarily from differences in heat and mass transfer, alterations in reaction kinetics, and the need for appropriate equipment design. At larger scales, heat transfer becomes inefficient due to reduced surface-to-volume ratios in reactors, potentially leading to hotspots and uneven temperature distributions that can cause side reactions or thermal runaway. Mass transfer limitations similarly intensify, as mixing in larger vessels is less effective, resulting in concentration gradients that alter reaction rates and yields compared to lab conditions. Reaction kinetics may shift during scale-up; for instance, reactions classified as Type A (fast, mass transfer-limited) in a continuous flow context require careful adjustment to avoid incomplete conversions, while Type B (moderate kinetics) benefit from enhanced mixing strategies. Equipment design plays a crucial role, with batch reactors offering flexibility for variable production but facing challenges in consistent heat removal, whereas continuous reactors provide steady-state operation but demand precise control of residence times to maintain kinetics. Safety protocols are integral to addressing these scalability issues, employing systematic methods to identify and mitigate risks. Hazard and Operability Studies (HAZOP) serve as a cornerstone, involving multidisciplinary teams that systematically analyze process deviations using guidewords like "no" or "more" to uncover potential hazards such as or leaks. principles further prioritize eliminating hazards at the source, such as substituting flammable solvents to avoid mixtures or minimizing inventory of reactive intermediates to reduce potential. tools like the Dow and Index quantify these dangers by assigning scores to factors including material reactivity and process conditions, enabling prioritization of safeguards like pressure relief systems. Process intensification techniques enhance by improving control and reducing hazards through compact, efficient designs. Microreactors exemplify this approach, leveraging high surface-to-volume ratios for superior heat and , which allows precise temperature regulation and minimizes the risk of exothermic runaway even at production scales. These devices facilitate safer handling of hazardous reactions by confining volumes to milliliters or less, preventing large-scale accumulation of or reactive , and enabling real-time monitoring for immediate adjustments. Impurity management during scale-up is critical to prevent runaway reactions, as uncontrolled byproducts can catalyze or alter thermal stability. Strategies include rigorous monitoring of reaction parameters like and to suppress byproduct formation, alongside in-process purification steps such as or to remove impurities that might accumulate and trigger autocatalytic effects. For example, in scaling hydrogenation processes, trace metal impurities from catalysts must be controlled through sequestration agents to avoid hotspots that could initiate runaways. Industrial-grade reagents often introduce unforeseen impurities, necessitating compatibility testing and gradual scale increments to identify and mitigate their impact on reaction safety. Regulatory compliance ensures that scalability and safety practices meet established standards, particularly in high-risk sectors. In the United States, the (OSHA) mandates under 29 CFR 1910.119, requiring hazard analyses, operating procedures, and mechanical integrity checks for processes involving highly hazardous chemicals. For pharmaceutical applications, the International Council for Harmonisation (ICH) guidelines, such as Q8(R2) on pharmaceutical development, emphasize risk-based approaches to scale-up, including design space definition to assure consistent quality and safety during manufacturing transitions. These frameworks integrate safety measures that, while adding initial design complexity, support overall process reliability without delving into detailed economic trade-offs.

Cost Optimization Strategies

Cost optimization in process chemistry involves strategies to reduce both material and conversion expenses while maintaining process efficiency and product quality. Material costs, which often constitute a significant portion of overall production expenses, are influenced by raw material sourcing, where selecting cost-effective suppliers and negotiating bulk purchases can lower procurement prices. Solvent recovery techniques, such as distillation or extraction, enable the reuse of organic solvents, reducing the need for fresh purchases and minimizing disposal fees; for instance, recovering up to 95% of solvents in pharmaceutical processes has been shown to cut material costs by 20-30%. Waste minimization through process redesign, like adopting greener synthetic routes, further decreases expenses by lowering the volume of byproducts that require treatment or disposal. Conversion costs encompass the expenses incurred during the transformation of raw materials into products, including direct labor for operating reactors and monitoring , for heating, cooling, and agitation, equipment over the asset's useful life, and overheads such as facility maintenance and utilities. In chemical , labor costs can be optimized by automating routine tasks, while energy efficiency measures like heat integration reduce utility bills, which may account for 10-20% of total conversion costs. is calculated using methods like straight-line allocation, ensuring accurate allocation of capital investments, and overheads are controlled through lean management practices to avoid unnecessary administrative burdens. Optimization techniques rely on advanced tools like software to model and predict cost impacts. Aspen Plus, a widely used simulator in , facilitates cost modeling by integrating thermodynamic data with economic evaluators to forecast capital and operating expenses, enabling scenario analysis for process modifications. Lifecycle analysis within such software assesses total ownership costs from design to decommissioning, helping identify bottlenecks like high-energy separations. Yield influences costs by directly affecting material utilization, with higher yields reducing per-unit expenses. The Quality Service Level (QSL) metric balances cost optimization with product reliability, defined as the percentage of batches meeting predefined purity and yield specifications, typically targeting >98% to minimize rework and ensure consistent quality. In process chemistry, maintaining high QSL prevents costly deviations that could arise from variable reaction conditions, thus safeguarding against production losses. A holistic approach to cost and performance evaluation is provided by the Process Excellence Index (PEI), which assesses process reproducibility and robustness. The PEI consists of two components: PEIyield=average yieldtarget yield×100%\text{PEI}_{\text{yield}} = \frac{\text{average yield}}{\text{target yield}} \times 100\% PEIcycle time=target cycle timeaverage cycle time×100%\text{PEI}_{\text{cycle time}} = \frac{\text{target cycle time}}{\text{average cycle time}} \times 100\% The overall PEI is the product of these values; it aids in comparing synthetic routes for economic viability, with values approaching 100% indicating optimal performance. Strategic decisions, such as versus in-house , further enhance cost optimization. to contract development and manufacturing organizations (CDMOs) can reduce capital expenditures on and labor by leveraging specialized facilities, potentially lowering costs by 15-40% for scale-up phases, though it may introduce coordination overheads. In contrast, in-house production offers greater control over and process customization but requires substantial upfront investments; the choice depends on production volume and alignment.

Evaluation Metrics

Economic Metrics

Economic metrics in process chemistry evaluate the financial viability and of synthetic routes, focusing on resource utilization and operational to guide scalable decisions. These indicators help chemists and engineers optimize processes by quantifying material , output rates, and cost structures, ensuring that developments translate effectively to industrial production without excessive financial burden. Atom economy measures the proportion of reactant atoms incorporated into the desired product, promoting waste-minimizing reaction designs. Introduced by Barry Trost, it is calculated as the percentage of the molecular weight of the product relative to the total molecular weight of all reactants: % atom economy=(molecular weight of product∑molecular weights of all reactants)×100\% \text{ atom economy} = \left( \frac{\text{molecular weight of product}}{\sum \text{molecular weights of all reactants}} \right) \times 100 This metric assumes stoichiometric reactant use and 100% yield, serving as a theoretical benchmark for comparing synthetic pathways in process development. Yield quantifies the efficiency of a reaction by comparing the actual amount of product obtained to the theoretical maximum, expressed as a percentage: yield=(moles of product obtainedmoles of product theoretically possible)×100\text{yield} = \left( \frac{\text{moles of product obtained}}{\text{moles of product theoretically possible}} \right) \times 100 In multi-step syntheses, stepwise yields refer to the efficiency of individual transformations, while overall yield is the product of all stepwise yields, highlighting how inefficiencies compound across stages. For instance, a sequence with three steps yielding 80%, 90%, and 70% respectively results in an overall yield of approximately 50%, underscoring the need for high yields in early steps to maintain process viability. Volume-time output (VTO) assesses process productivity by relating the reactor space and time required to produce a unit mass of product, a critical factor for industrial where values below 1 m³ h kg⁻¹ are targeted to minimize facility footprint and cycle times. The formula is: VTO=reactor volume×timemass of product\text{VTO} = \frac{\text{reactor volume} \times \text{time}}{\text{mass of product}} In flow chemistry applications, low VTO values indicate efficient space utilization, as seen in continuous processes for active pharmaceutical ingredients where VTO guides design to balance throughput and quality. Material cost represents the direct expenses for raw materials and per unit of product, calculated by summing the quantities required (adjusted for yield and ) multiplied by their unit prices, then divided by the product output. This metric drives route selection in pharmaceutical process chemistry, where volatile prices for specialty can dominate budgets; tools like bill-of-materials software facilitate these computations to forecast . Conversion cost encompasses all operational expenses to transform raw materials into product, excluding material costs, and is subdivided into categories such as (utilities and heating/cooling), labor (personnel and ), and overhead (, , and handling). In chemical , these costs are derived from operating expenditure models, often comprising 20-50% of total production expenses depending on process intensity, and are minimized through and energy-efficient designs.

Environmental and Efficiency Metrics

Process chemistry employs several key metrics to evaluate the environmental and of synthetic processes, focusing on waste generation, resource utilization, and broader ecological impacts. These metrics help chemists and engineers design processes that minimize environmental footprints while optimizing performance, aligning with the broader goals of . Unlike purely economic assessments, these tools emphasize holistic impacts such as burdens and energy demands. The E-factor, introduced by Roger Sheldon in 1992, quantifies waste production as the ratio of total waste mass to the mass of the desired product in kilograms, providing a direct measure of process inefficiency. E-factor=total waste (kg)mass of product (kg)\text{E-factor} = \frac{\text{total waste (kg)}}{\text{mass of product (kg)}} An ideal E-factor is zero, reflecting no waste, though pharmaceutical processes often range from 25–100 due to complex purifications. This metric has driven innovations in waste minimization, with lower values indicating reduced environmental disposal needs. Process mass intensity (PMI) extends this by assessing overall resource use, defined as the total mass of materials input (including reagents, solvents, and water) divided by the mass of product output. PMI=total mass input (kg)mass of product (kg)\text{PMI} = \frac{\text{total mass input (kg)}}{\text{mass of product (kg)}} Developed by the ACS Green Chemistry Institute Pharmaceutical Roundtable, PMI benchmarks "greenness" across industries, with values below 50 considered efficient for fine chemicals; for example, solvent recovery can reduce PMI by 20–30% in multi-step syntheses. It correlates closely with E-factor (PMI = E-factor + 1) but includes all inputs for a fuller sustainability profile. The EcoScale offers a semi-quantitative , starting from a perfect score of 100 and deducting penalties for factors like yield (below 100% subtracts up to 50 points), of materials, hazards, and use in technical setup. EcoScale=100−∑(penalties for yield, [price](/page/Price), [safety](/page/Safety), technical setup)\text{EcoScale} = 100 - \sum \text{(penalties for yield, [price](/page/Price), [safety](/page/Safety), technical setup)} Proposed by Van Aken et al. in 2006, it aids rapid screening of synthetic routes, classifying scores above 75 as "excellent" green processes; for instance, a high-yield catalytic reaction might score 80, penalizing only for minor costs. This tool integrates environmental and practical considerations without requiring full . Beyond mass-based metrics, process efficiency encompasses cycle time reduction and energy optimization, which lower operational footprints by accelerating throughput and minimizing heating or cooling demands. For example, continuous flow systems can halve cycle times compared to batch processes, reducing energy use by up to 40% in reactions like hydrogenations. Solvent selection plays a pivotal role here, favoring low-volatility options like over volatile hydrocarbons to cut energy by 15–25%, as guided by life-cycle assessments. These metrics are deeply informed by the 12 principles of , articulated by and in 1998, which prioritize waste prevention, catalysis over stoichiometric reagents, and safer solvents to enhance . Principle 1 (prevention) directly underpins E-factor and PMI by targeting , while Principle 9 (catalytic reagents) boosts EcoScale scores through efficient, reusable catalysts that reduce mass inputs. Integration of these principles ensures metrics evolve with , fostering quantifiable improvements in environmental performance.

Case Studies

Pharmaceutical Applications

Process chemistry plays a pivotal role in pharmaceutical manufacturing, where the focus is on developing scalable, safe, and efficient synthetic routes for active pharmaceutical ingredients (APIs) that meet stringent regulatory standards for purity, stereochemistry, and environmental impact. Unlike high-volume commodity chemicals, pharmaceutical production emphasizes low-volume, high-value molecules, often requiring complex multi-step syntheses to achieve specific biological activity. Key challenges include chiral synthesis to ensure the correct enantiomer predominates, polymorph control to maintain consistent physical properties and bioavailability, and achieving API purity exceeding 99.5% to minimize impurities that could affect efficacy or safety. A notable is the development of the HCV inhibitor BI 201302 by , where process chemists optimized the synthetic route to address inefficiencies in the initial approach. Through strategic modifications, including a ruthenium-catalyzed ring-closing metathesis for macrocyclization and an SNAr displacement for installation, the process was streamlined, enhancing and . Another landmark example is Merck's synthesis of sitagliptin, the in the drug Januvia, which incorporated biocatalysis to supplant traditional chemical methods. The enzymatic , developed in collaboration with Codexis, utilized an evolved ketoreductase and to convert a prochiral to the chiral intermediate via , replacing a rhodium-catalyzed that relied on precious metals. This biocatalytic route achieved an 82% yield with 99% enantiomeric excess (), significantly improving and eliminating hazardous reagents while increasing productivity by 53%. Pharmaceutical process chemistry also navigates substantial regulatory hurdles, particularly FDA requirements for process validation to ensure reproducibility and quality control throughout the product lifecycle. Implementation of Process Analytical Technology (PAT) enables real-time monitoring of critical quality attributes, such as reaction completion and impurity profiles, facilitating compliant scale-up from lab to commercial production. Cost optimization in pharmaceutical routes often involves minimizing reliance on expensive reagents, exemplified by efforts to reduce precious metal catalysts in cross-coupling reactions. For instance, in the synthesis of various APIs, ligand modifications or alternative methodologies have lowered palladium or platinum loadings from several mol% to sub-stoichiometric levels, yielding cost savings of up to 50% per batch while maintaining high yields and selectivities.

Bulk and Fine Chemical Examples

Process chemistry in bulk and fine chemical manufacturing exemplifies the transition from laboratory-scale synthesis to industrial production, prioritizing , yield, and waste minimization in high-volume operations. Aspirin (acetylsalicylic acid) production, initiated by in 1899 through of with , has scaled to global volumes of approximately 50,000 tons annually, demonstrating the adaptability of batch processes to continuous manufacturing for commoditized pharmaceuticals. Modern optimizations incorporate flow reactors, achieving yields of 85-95% by enabling precise control over reaction conditions and reducing side products like acetic acid. Ibuprofen synthesis highlights advancements in greener for fine chemicals with pharmaceutical overlap. The original Boots-Hoechst-Celanese (BHC) route from the employed a six-step starting from isobutylbenzene, generating significant —up to 3.4 kg per kg of product—due to stoichiometric reagents and multiple isolations. In the 1990s, BHC developed a three-step catalytic alternative using as a recyclable catalyst-solvent in the initial Friedel-Crafts , followed by and , which reduced to less than 1 kg per kg of ibuprofen, a 70% decrease, while doubling . Bulk chemicals like illustrate process chemistry at massive scales, where Ziegler-Natta enables efficient of into (HDPE). This titanium-based supported catalyst system, developed in the , operates in low-pressure or gas-phase reactors, producing over 100 million tons globally each year with energy efficiencies improved by 30-50% compared to earlier high-pressure free-radical methods through optimized heat integration and catalyst activity. Catalyst recycling focuses on minimizing titanium residues in the via filtration and supports like , reducing operational costs and environmental impact without compromising molecular weight control. In fine chemicals, fragrance synthesis such as production addresses niche demands with stringent purity requirements. Synthetic , primarily derived from via the Reimer-Tiemann reaction or oxidation, yields around 15,000 tons annually, with processes emphasizing and to achieve >99% purity by removing impurities like o-vanillin and syringaldehyde that affect aroma profiles. Seasonal demand fluctuations, driven by and industries, necessitate flexible batch operations to manage and avoid overproduction, contrasting with steady-state bulk processes. Scale differences underscore process chemistry's adaptability: bulk operations like handle million-ton reactors with continuous flow for economic viability, while fine chemicals like use kilo- to ton-scale batch reactors for purity and customization; pharmaceutical production, by comparison, often limits to multi-kilo scales per campaign due to regulatory constraints, amplifying per unit.

Advanced Methodologies

Catalytic Techniques

Catalytic techniques play a pivotal role in process chemistry by enabling efficient carbon-carbon bond formation and selective transformations at scale, with transition-metal and organocatalytic methods reducing reaction steps and improving yields in synthetic routes. These approaches address key challenges in , such as efficiency and impurity control, while integrating recovery strategies to minimize costs and environmental impact. Transition-metal , particularly -catalyzed cross-couplings, has revolutionized process chemistry through robust C-C bond formations. The Suzuki-Miyaura reaction exemplifies this, coupling arylboronic acids or esters with aryl halides in the presence of a catalyst and base, as shown in the general equation: \ceAr−B(OH)2+Ar′−X−>Ar−Ar′+HX\ce{Ar-B(OH)2 + Ar'-X -> Ar-Ar' + HX} This reaction proceeds via , , and steps, often using s like to stabilize the catalyst. issues arise from factors such as and ; for instance, at high altitudes, vessels are required to maintain conditions around 90°C, while improper ligand liberation can lead to Pd(0) formation and impurities. Optimized conditions, including 1 mol% Pd(PPh₃)₂Cl₂ loading with 2-butanol/water solvent and K₂CO₃ base, have achieved 89.6% yields at lab scale and satisfactory results at 50 kg, though residual levels (up to 1120 ppm) necessitate post-reaction treatments like O₂/N₂ bubbling and L-cysteine scavenging to reduce leaching below 100 ppm. screening further enhances efficiency, enabling short cycle times and Pd removal to ≤100 ppm via /NaHSO₃ extraction on 20-L scale. Organocatalysis offers a metal-free alternative, leveraging small organic molecules for enantioselective transformations without toxicity concerns associated with metals. Proline-catalyzed aldol reactions, for example, promote the addition of enolizable carbonyls to aldehydes, forming β-hydroxy carbonyl products through intermediates, achieving high enantioselectivity in asymmetric synthesis. Key advantages include insensitivity to moisture and oxygen, low cost, non-, and minimal catalyst loading (often 5-30 mol%), which avoids metal contamination and supports greener processes compared to transition-metal systems. These reactions build complex molecular frameworks efficiently, with applications in constructing stereocenters for pharmaceuticals. Process integration enhances catalytic techniques through catalyst recovery and reactor designs tailored for continuous operation. Supported catalysts, prepared via impregnation or deposition-precipitation methods, immobilize metals on inert carriers like silica or carbon, facilitating easy separation by and reuse. For instance, pore volume impregnation ensures homogeneous metal distribution (e.g., 1-3 wt% Pd), while under controlled gas flows (e.g., NO/He) yields small particles (4 nm) for improved recyclability. Reactor designs, such as fixed-bed systems, enable continuous flow of reactants over supported s, reducing downtime and enhancing throughput in industrial settings. A representative example is the scaling of Negishi coupling for active pharmaceutical ingredient (API) synthesis, where arylzinc reagents couple with aryl halides using palladium catalysis. In the production of PDE472, a phosphodiesterase type 4D inhibitor, preformation of the arylpalladium complex allowed pilot-plant scale execution, reducing synthetic steps and residual Pd to <2 ppm via crystallization, thereby lowering costs and improving purity. Challenges in these techniques include metal leaching and recyclability, particularly in palladium systems where catalyst deactivation limits reuse. Leaching occurs via dissolution of metal atoms into solution, often during oxidative addition, compromising product purity and necessitating scavengers. Recyclability metrics show supported Pd nanoparticles maintaining activity over 5-9 cycles in cross-couplings (e.g., 93-99% yields in cyanation), but overall efficiency drops if stabilization (e.g., by polymers) fails, highlighting the need for robust supports to achieve >80% activity retention after multiple runs.

Biocatalytic and Flow Processes

Biocatalysis employs enzymes to catalyze chemical reactions under mild conditions, offering high specificity and efficiency in process chemistry. Enzymatic reactions, such as those mediated by s, are particularly valuable for esterification processes, where lipases hydrolyze or synthesize esters at the water-oil interface, enabling the production of industrially important compounds like emulsifiers and biofuels. For instance, Candida antarctica lipase B (CALB) has been widely used for the regioselective of sugars and the synthesis of short-chain esters, achieving yields exceeding 90% in non-aqueous media. To enhance enzyme performance for industrial applications, protein engineering techniques like are applied to improve stability, activity, and selectivity under non-natural conditions such as extreme pH or temperatures. involves iterative rounds of random and screening, resulting in variants of lipases and esterases that maintain activity at elevated temperatures up to 60°C or in organic solvents, significantly extending operational lifetimes in continuous processes. Advanced tools, including CRISPR-based , facilitate the creation of custom enzyme libraries by enabling precise modifications to microbial hosts for expressing tailored biocatalysts, accelerating the development of robust variants for synthetic pathways. A prominent example is the production of statins, where Codexis engineered an acyltransferase enzyme through to perform the selective butylation of , enabling an efficient biocatalytic step in simvastatin synthesis that reduced waste and achieved yields of over 97% with purity exceeding 99% at multi-kilogram scales. Continuous flow manufacturing represents a in process chemistry, utilizing systems to deliver precise control over reaction parameters like temperature, mixing, and , which is defined as the average duration a reactant spends in the and calculated by the : τ=VF\tau = \frac{V}{F} where τ\tau is the , VV is the reactor volume, and FF is the . This approach minimizes residence times to seconds or minutes, reducing side and enabling safe handling of hazardous intermediates, while offering from lab to production without proportional increases in equipment size. Hybrid approaches integrate biocatalysis with flow chemistry to streamline multi-step syntheses, immobilizing enzymes in microreactors or packed-bed columns to facilitate sequential reactions with in-line purification. For example, immobilized lipases in flow systems have been used for continuous esterification cascades, combining enzymatic steps with chemical transformations to produce pharmaceutical intermediates with enhanced productivity and minimal downtime. These hybrid methods achieve higher selectivity—often >95%—and lower energy consumption compared to traditional batch processes, as flow eliminates heating/cooling cycles and optimizes mass transfer.

Research and Future Directions

Academic and Industrial Institutes

Process chemistry research and education are advanced by several prominent academic centers. The Novartis-MIT Center for Continuous Manufacturing was established in 2007 through a 10-year partnership between the Massachusetts Institute of Technology (MIT) and , focusing on developing integrated continuous manufacturing technologies for pharmaceuticals and emphasizing flow processes to enhance efficiency and in production; its work continues through spin-offs such as CONTINUUS Pharmaceuticals. Similarly, ETH Zurich's Institute for Chemical and Bioengineering provides foundational education and research in the design and operation of industrial chemical processes, integrating bioengineering principles to support sustainable process development. In the industrial sector, key laboratories drive innovation for large-scale production. Pfizer's organization includes dedicated process development teams that optimize synthetic routes and for small-molecule drugs, ensuring and cost-effectiveness across global sites. GlaxoSmithKline (GSK) maintains API development centers as part of its worldwide R&D network, with facilities in the UK, , and focused on scaling active pharmaceutical ingredient synthesis while incorporating advanced technologies. Collaborative initiatives bridge academia and industry to foster process chemistry advancements. The (ACS) Institute, through its Pharmaceutical Roundtable, promotes sustainable by funding research on greener synthetic methods and process intensification for pharmaceutical manufacturing. The European Union's program allocates significant funding—over €93.5 billion overall—for research and innovation in sustainable chemicals and materials, supporting process R&D projects aimed at reducing environmental impacts in chemical production. Educational programs in departments increasingly emphasize (QbD) principles to train future process chemists in systematic process development and . For instance, curricula at institutions like integrate QbD into master's programs in , focusing on designing robust manufacturing processes from the outset to ensure product quality and efficiency. Notable contributions from research institutes highlight scalable applications in process chemistry. The Scripps Research Institute, particularly through the laboratory of , has pioneered scalable total syntheses of complex natural products, such as ingenol and , enabling practical production routes that address challenges in yield and complexity for potential therapeutic agents. In process chemistry, the integration of (AI) and (ML) is transforming synthetic route prediction and process optimization. Tools like RXN for Chemistry employ transformer-based models to perform retrosynthesis, predicting multi-step synthetic pathways from target molecules with high accuracy, enabling chemists to explore thousands of potential routes rapidly. Similarly, AI-driven real-time optimization uses sensor data and ML algorithms to adjust process parameters dynamically, such as and flow rates in continuous manufacturing. These digital advancements address longstanding challenges in route scouting and scale-up by providing predictive insights that minimize trial-and-error experimentation. Sustainability efforts are advancing through the integration of carbon capture technologies directly into chemical processes, known as reactive capture, where CO2 is captured and converted in a single step without intermediate purification, enhancing efficiency in industries like . Concurrently, principles are gaining traction with bio-based feedstocks, such as , which replace fossil resources in processes to produce platform chemicals like , closing material loops and reducing by 50-70% compared to routes. These approaches promote and , with examples including mass-balance allocation systems that blend bio-feedstocks into existing production chains for scalable implementation. Regulatory frameworks are evolving to support these innovations, exemplified by the U.S. Food and Drug Administration's (FDA) 2023 Advanced Manufacturing Technologies Designation Program, which incentivizes the adoption of modular facilities and continuous manufacturing to enhance pharmaceutical and product quality. This initiative provides expedited review pathways for technologies like plug-and-play modular reactors, facilitating faster deployment in response to global demands. Post-2020 supply chain disruptions, particularly during the , accelerated process chemistry adaptations for rapid scaling, as seen in mRNA vaccine production where lipid nanoparticle formulation and purification processes were optimized to deliver over 3 billion doses of Comirnaty in 2021 through decentralized manufacturing networks. These efforts highlighted the need for flexible, resilient processes to mitigate bottlenecks in raw materials and , influencing broader trends toward localized production in process chemistry. Emerging trends also emphasize computational chemistry's role in process design, with neural network potentials enabling faster simulations of molecular interactions to predict reaction outcomes and material properties, as demonstrated in recent advancements that accelerate discovery by orders of magnitude. In personalized medicine, process chemistry is shifting toward on-demand synthesis using flow reactors and 3D-printed devices to produce patient-specific drug formulations, such as customized dosages of biologics, integrating genomic data for targeted therapies. These developments, underrepresented in traditional frameworks, underscore a move toward data-driven, individualized chemical paradigms.

References

  1. https://pubs.acs.org/doi/10.1021/cr068400d
  2. https://www.acs.org/careers/chemical-sciences/fields/process-chemistry.html
  3. https://learning.acsgcipr.org/foundation/introduction-to-process-chemistry-in-the-pharmaceutical-industry/
  4. https://researcher-resources.acs.org/publish/author_guidelines?coden=oprdfk
  5. https://pubs.acs.org/doi/10.1021/bk-2022-1426.ch001
  6. https://pubs.acs.org/doi/10.1021/acs.oprd.1c00477
  7. https://pubs.acs.org/doi/full/10.1021/op060164l
  8. https://books.rsc.org/books/edited-volume/1895/chapter/2487175/Continuous-Crystallization-of-Bulk-and-Fine
  9. https://www.sciencedirect.com/topics/engineering/bulk-chemical
  10. https://pubs.acs.org/doi/10.1021/acs.oprd.5c00040
  11. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q7a-good-manufacturing-practice-guidance-active-pharmaceutical-ingredients
  12. https://pubs.acs.org/doi/10.1021/op300159y
  13. https://www.sciencehistory.org/education/scientific-biographies/william-henry-perkin/
  14. https://www.sciencehistory.org/education/scientific-biographies/alfred-nobel/
  15. https://www.aiche.org/resources/publications/cep/2016/september/introduction-ammonia-production
  16. https://www.nobelprize.org/prizes/chemistry/1909/ostwald/facts/
  17. https://www.acs.org/education/whatischemistry/landmarks/penicillin.html
  18. https://www.nobelprize.org/uploads/2018/06/advanced-chemistryprize2001.pdf
  19. https://www.acs.org/green-chemistry-sustainability/what-is-green-chemistry/history-of-green-chemistry1.html
  20. https://www.epa.gov/clean-air-act-overview/clean-air-act-requirements-and-history
  21. https://pmc.ncbi.nlm.nih.gov/articles/PMC4133758/
  22. https://www.sciencedirect.com/science/article/abs/pii/S138589471630345X
  23. https://stolichem.com/scale-up-flow-chemistry/
  24. https://pubs.acs.org/doi/10.1021/op5001918
  25. https://pmc.ncbi.nlm.nih.gov/articles/PMC8130218/
  26. https://www.sciencedirect.com/topics/chemistry/hazard-and-operability-study-process-safety
  27. https://www.aiche.org/resources/publications/cep/2003/october/reduce-dust-explosions-inherently-safer-way
  28. https://www.aiche.org/resources/publications/books/dows-fire-explosion-index-hazard-classification-guide-7th-edition
  29. https://www.sciencedirect.com/science/article/abs/pii/S1385894725060590
  30. https://pubs.acs.org/doi/10.1021/op034193x
  31. https://www.mt.com/us/en/home/applications/L1_AutoChem_Applications/Process-Safety.html
  32. https://pubs.acs.org/doi/10.1021/bk-2014-1181.ch001
  33. https://www.academia.edu/90861773/Safe_chemical_reaction_scale_up
  34. https://www.osha.gov/laws-regs/regulations/standardnumber/1910/1910.119
  35. https://database.ich.org/sites/default/files/Q8%2528R2%2529%2520Guideline.pdf
  36. https://www.sciencedirect.com/science/article/pii/S2589004221010828
  37. https://gwsionline.com/solvent-recovery/
  38. https://p2infohouse.org/ref/33/32302.pdf
  39. https://www.wallstreetmojo.com/conversion-cost/
  40. https://www.accountingtools.com/articles/what-are-conversion-costs.html
  41. https://egrove.olemiss.edu/cgi/viewcontent.cgi?article=1113&context=acct_inst
  42. https://www.aspentech.com/en/products/engineering/aspen-plus
  43. https://www.rishabheng.com/blog/process-modeling-using-aspen-plus-software/
  44. https://pubs.acs.org/doi/10.1021/op300144g
  45. https://www.netsuite.com/portal/resource/articles/erp/in-house-manufacturing-vs-outsourcing.shtml
  46. https://www.idbs.com/knowledge-base/contract-manufacturing-vs-in-house-production/
  47. https://www.science.org/doi/10.1126/science.1962206
  48. https://pubs.acs.org/doi/10.1021/acs.jchemed.5c00296
  49. https://pubs.acs.org/doi/10.1021/acs.oprd.8b00199
  50. https://pubs.acs.org/doi/10.1021/acs.jcim.3c01524
  51. https://pubs.acs.org/doi/10.1021/acs.chemrev.1c00332
  52. https://www.sciencedirect.com/science/article/pii/S2589004222001626
  53. https://pubs.acs.org/doi/10.1021/op049933w
  54. https://pubs.acs.org/doi/10.1021/op0500180
  55. https://www.sciencedirect.com/science/article/abs/pii/B9780444643377000094
  56. https://pubs.acs.org/doi/10.1021/bk-2016-1233.ch003
  57. https://pubs.rsc.org/en/content/articlelanding/2017/gc/c6gc02157c
  58. https://pubs.rsc.org/en/content/articlelanding/2007/gc/b713736m
  59. https://pubs.acs.org/doi/10.1021/op200097d
  60. https://pubs.rsc.org/en/content/articlehtml/2014/gc/c3gc42513d
  61. https://pubs.acs.org/doi/10.1021/acssuschemeng.4c05521
  62. https://pubs.acs.org/doi/10.1021/ol400140r
  63. https://www.epa.gov/greenchemistry/presidential-green-chemistry-challenge-2010-greener-reaction-conditions-award
  64. https://www.bayer.com/en/news-stories/125-years-of-acetylsalicylic-acid
  65. https://learncheme.com/wp-content/uploads/Prausnitz/QualityofLife/PainReliefEverybodyAspirin.pdf
  66. https://www.chemanalyst.com/NewsAndDeals/NewsDetails/inside-the-chemistry-industrial-production-process-of-aspirin-38477
  67. https://www.epa.gov/greenchemistry/presidential-green-chemistry-challenge-1997-greener-synthetic-pathways-award
  68. https://link.springer.com/article/10.1007/s10698-017-9300-9
  69. https://pmc.ncbi.nlm.nih.gov/articles/PMC5455813/
  70. https://www.nature.com/articles/s41467-022-32635-z
  71. https://www.sciencedirect.com/science/article/pii/S2949839225000926
  72. https://files.core.ac.uk/download/pdf/145050730.pdf
  73. https://capitalresin.com/bulk-chemicals-vs-fine-chemicals-the-difference/
  74. https://chemanager-online.com/en/topics/essential-ingredients
  75. https://pubs.acs.org/doi/10.1021/acs.oprd.5c00207
  76. https://pubs.acs.org/doi/10.1021/op800064y
  77. https://www.longdom.org/open-access/proline-catalysed-aldol-reaction-related-with-organocatalysis-95135.html
  78. https://pubs.acs.org/doi/10.1021/cr500486u
  79. https://pubs.acs.org/doi/10.1021/op025615q
  80. https://www.mdpi.com/1420-3049/15/7/4792
  81. https://www.mdpi.com/2073-4344/15/4/375
  82. https://www.tandfonline.com/doi/abs/10.1081/CR-120015481
  83. https://pmc.ncbi.nlm.nih.gov/articles/PMC3351540/
  84. https://www.sciencedirect.com/science/article/abs/pii/S0076687904880182
  85. https://www.creative-biogene.com/crispr-cas9/solution/advancing-enzyme-directed-evolution-with-crispr-technology.html
  86. https://www.mdpi.com/2073-4344/9/3/260
  87. https://www.mt.com/us/en/home/applications/L1_AutoChem_Applications/continuous-flow-chemistry.html
  88. https://chemistry-europe.onlinelibrary.wiley.com/doi/10.1002/open.201500018
  89. https://pmc.ncbi.nlm.nih.gov/articles/PMC6441135/
  90. https://pubs.rsc.org/en/content/articlehtml/2021/re/d0re00483a
  91. https://www.chimia.ch/chimia/article/download/2025_411/2025_411
  92. https://news.mit.edu/2007/novartis-0928
  93. https://www.continuuspharma.com/discover-continuus/our-ecosystem/
  94. https://chab.ethz.ch/en/research/institutes/ICB.html
  95. https://www.pfizer.com/science
  96. https://www.gsk.com/en-gb/innovation/rd-locations/
  97. https://acsgcipr.org/
  98. https://environment.ec.europa.eu/topics/chemicals/funding-chemicals-strategy_en
  99. https://che.northeastern.edu/academics/graduate-studies/ms-phce/
  100. https://pubs.rsc.org/en/content/articlehtml/2014/np/c3np70090a
  101. https://research.ibm.com/blog/thieme-rxn-for-chemistry
  102. https://www.chemcopilot.com/blog/process-optimization-and-efficiency-in-the-chemical-industry-from-ai-to-continuous-flow
  103. https://www.sciencedirect.com/science/article/abs/pii/B9780443152740500731
  104. https://www.sciencedirect.com/science/article/pii/S2542435123001253
  105. https://pubs.rsc.org/en/content/articlelanding/2022/gc/d1gc04758b
  106. https://www.iscc-system.org/wp-content/uploads/2022/04/Mass-Balance-White-Paper.pdf
  107. https://www.fda.gov/media/174651/download
  108. https://www.morganlewis.com/blogs/asprescribed/2023/12/fda-rounds-out-2023-with-advanced-manufacturing-technologies-designation-program-guidance
  109. https://www.nature.com/articles/s41587-022-01643-1
  110. https://www.gao.gov/products/gao-21-319
  111. https://news.mit.edu/2025/new-computational-chemistry-techniques-accelerate-prediction-molecules-materials-0114
  112. https://link.springer.com/article/10.1007/s44395-025-00011-7
  113. https://www.pnas.org/doi/10.1073/pnas.2415655121
Add your contribution
Related Hubs
User Avatar
No comments yet.